ArticleMolecular neurobiology2026
Modulation of Oxidative Stress and Apoptosis by Antrodia cinnamomea-Loaded Citrate-Stabilized Silver Nanoparticles in Experimental Parkinsonism.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuron loss in the substantia nigra pars compacta, accompanied by oxidative stress and neuroinflammation. Novel multitarget neuroprotective strategies are required to overcome the limitations of current symptomatic treatments. The neuroprotective effects of Antrodia cinnamomea (AC) and citrate-stabilized silver nanoparticles (AgNPs), alone and in combination, were evaluated using a 6-hydroxydopamine (6-OHDA)-induced SH-SY5Y cell model and a unilateral 6-OHDA rat model. Sixty-three rats were divided into nine experimental groups. Cell viability, behavioral tests, LC-MS/MS analysis of dopamine and acetylcholine, oxidative stress and inflammatory biomarkers, histopathological assessment, immunohistochemistry, and Western blot analyses of TH, α-synuclein, PI3K, Bcl-2, Caspase-3, and agmatinase were performed. 6-OHDA significantly reduced cell viability, impaired motor performance, and induced dopaminergic neuronal degeneration. AC treatment, particularly in combination with AgNPs, markedly improved cell survival, ameliorated behavioral deficits, and preserved neuronal architecture. Combined treatment significantly decreased MDA, TNF-α, and IL-1β levels, while restoring GSH and SOD activities. LC-MS/MS analysis demonstrated partial recovery of dopamine and acetylcholine levels. Increased TH and PI3K expression, reduced α-synuclein and Caspase-3 levels, and normalization of Bcl-2 and agmatinase were observed following AC + AgNP treatment. AC conjugated with citrate-stabilized AgNPs exerts significant neuroprotective effects in experimental PD by concurrently modulating oxidative stress, neuroinflammation, and apoptotic pathways, highlighting its potential as a multitarget therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.